Morgan Stanley
ARGS

Morgan Stanley’s Argos Therapeutics, Inc. ARGS Stock Holding History

Morgan Stanley’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-514
Closed -$2K – 6916
2017
Q4 		$2K Buy
+514
New +$1.72K ﹤0.01% 6471
2017
Q3 		– Sell
-2,660
Closed -$19K – 6825
2017
Q2 		$19K Buy
2,660
+1,773
+200% +$15.1K ﹤0.01% 6109
2017
Q1 		$8K Sell
887
-1,677
-65% -$106K ﹤0.01% 6288
2016
Q4 		$251K Sell
2,564
-1,272
-33% -$119K ﹤0.01% 5263
2016
Q3 		$381K Buy
3,836
+3,137
+449% +$328K ﹤0.01% 4686
2016
Q2 		$85K Buy
699
+144
+26% +$19.2K ﹤0.01% 5316
2016
Q1 		$71K Buy
+555
New +$44.9K ﹤0.01% 5473
2015
Q2 		– Sell
-41
Closed -$7K – 7027
2015
Q1 		$7K Hold
41
– – ﹤0.01% 6302
2014
Q4 		$8K Buy
41
+2
+5% +$360 ﹤0.01% 6262
2014
Q3 		$8K Sell
39
-5
-11% -$781 ﹤0.01% 6259
2014
Q2 		$7K Sell
44
-1,782
-98% -$295K ﹤0.01% 6260
2014
Q1 		$365K Buy
+1,826
New +$365K ﹤0.01% 4768

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Morgan Stanley's ARGS Position: Q1 2018 in Review

Morgan Stanley sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2018, closing a stake of 514 shares — an estimated $2K sold.

Morgan Stanley first reported a position in ARGS in Q1 2014 and held it in 12 quarters. The position peaked at $381K in Q3 2016. 16 funds tracked by Wall St. Rank hold ARGS as of Q1 2018.

  • Morgan Stanley reported no remaining Argos Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Morgan Stanley sold 514 Argos Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
  • Morgan Stanley first reported a position in Argos Therapeutics, Inc. in Q1 2014 and held it in 12 quarters.
  • Morgan Stanley's Argos Therapeutics, Inc. position peaked at $381K in Q3 2016.
  • 16 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2018.

Based on Morgan Stanley's 13F filing for Q1 2018, filed 14 May 2018.